This article focuses on a crucial development in genetic research that occurred in the 1990s: the identification of the first two of the genes responsible for hereditary breast and ovarian cancer (BRCA1 and BRCA2). Issues addressed touch on the evolution of the subfield, its potential impact on cancer treatment, and industry involvement. The article follows the activities of the various research groups competing in the race to identify the genes and depicts the frequent conflicts between them. Data are derived chiefly from a bibliometric database. The results show a diversity of research practices. Industrial researchers interacted within far more tightly knit networks than their counterparts working in public organizations. The patenting and commercial exploitation of results led to fierce battles, with one group capturing most of the benefits.
Get full access to this article
View all access options for this article.
References
1.
Anderson, D.E. 1972. A genetic study of human breast cancer. Journal of the National Cancer Institute48: 1029-34.
2.
Angier, N. 1994. Scientists identify a mutant gene tied to hereditary breast cancer. The New York Times, 15 September, A1, B7.
3.
Armstrong, K., A. Eisen, and B. Weber. 2000. Primary care: Assessing the risk of breast cancer. The New England Journal of Medicine342: 564-71.
4.
The Associated Press. 1994. U.S., Utah firm clash over rights to gene. The Salt Lake Tribune, 29 October.
5.
Blumenthal, D., E.G. Campbell, M.S. Anderson, N. Causino, and K. Seashore Louis. 1997. Withholding research results in academic life science. Journal of the American Medical Association, 277: 1224-28.
6.
Blumenthal, D., N. Causino, and E.G. Campbell. 1997. Academic-industry research relationship in genetics: A field apart. Nature Genetics16: 104-8.
7.
The Breast Cancer Linkage Consortium. 1997. Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. The Lancet, 349: 1505-10.
8.
Breast cancer on the brink. 1993. Nature Genetics5: 101-2.
9.
Bronchud, M.H., M. Foote, and W.P. Peters, eds. 2000. Principles of molecular oncology. Totowa, NJ: Humana.
10.
Bunk, S. 1999. Researchers feel threatened by disease gene patents. The Scientist13: 7.
11.
Butler, D., and D. Gershon. 1994. Breast cancer discovery sparks new debate on patenting human genes. Nature371: 271-72.
12.
Butler, D., and S. Goodman. 2001. French researchers take a stand against cancer gene patent. Nature413: 95-96.
13.
Davies, K. 2001. Cracking the genome: Inside the race to unlock human DNA. New York: Free Press.
14.
Davies, K., and M. White. 1996. Breakthrough: The race to find the breast cancer gene. New York: John Wiley.
15.
Dickson, D. 1995. Open access to sequence data “will boost hunt for breast cancer gene.” Nature378: 425.
Elwood, J.M. 1999. Santé publique et dépistage génétique du cancer du sein au Canada—Première partie: Risques et interventions. Maladies Chroniques au Canada20: 4-16.
18.
Fujimura, J.H. 1996. Crafting science: A sociohistory of the quest for the genetics of cancer. Cambridge, MA: Harvard University Press.
19.
Garrety, K. 1997. Social worlds, actor-networks and controversy: The case of cholesterol, dietary fat and heart disease. Social Studies of Science27: 727-73.
20.
The glittering prize. 1994. Nature Genetics8: 105-6.
21.
Healy, B. 1997. BRCA genes—Bookmaking, fortunetelling, and medical care. The New England Journal of Medicine336: 1448-49.
22.
Hilgartner, S. 1995. The Human Genome Project. In Handbook of science and technology studies, edited by S. Jasanoff, G.E. Markle, J.C. Peterson, and T. Pinch, 302-15. Thousand Oaks, CA: Sage.
Hubbard, R., and E. Ward. 1993. Exploding the gene myth: How genetic information is produced and manipulated by scientists, physicians, employers, insurance companies, educators, and law enforcers. Boston: Beacon.
25.
Jensen, R.A., M.E. Thompson, T.L. Jetton, C.I. Szabo, R. van der Meer, B. Helou, S.R. Tronick, D.L. Page, M.-C. King, and J.T. Holt. 1996. BRCA1 is secreted and exhibits properties of a granin. Nature Genetics12: 303-8.
26.
Kenney, M. 1986. Biotechnology: The university-industrial complex. New Haven, CT: Yale University Press.
27.
Kinzler, K.W., and B. Vogelstein. 1997. Gatekeepers and caretakers. Nature386: 761-62.
28.
Kotulak, R. 1999. Biotech firms say they need protection. Chicago Tribune, 12 September, 1.
29.
Lerman, C., S. Narod, K. Schulman, C. Hughes, A. Gomez-Caminero, G. Bonney, K. Gold, B. Trock, D. Main, J. Lynch, C. Fulmore, C. Snyder, S.J. Lemon, T. Conway, P. Tonin, G. Lenoir, and H. Lynch. 1996. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. Journal of the American Medical Association275: 1885-92.
30.
Lewis, R. 2001. Founder populations fuel gene discovery. The Scientist15: 8.
31.
Lynch, H.T., R.E. Harris, H.A. Guirgis, K. Maloney, L.L. Carmody, and J.F. Lynch. 1978. Familial association of breast/ovarian carcinoma. Cancer41: 1543-49.
32.
Marshall, E. 1997. The battle over BRCA1 goes to court; BRCA2 may be next. Science278: 1874.
33.
Martin, A.-M., and B.L. Weber. 2000. Genetic and hormonal risk factors in breast cancer. Journal of the National Cancer Institute92: 1126-35.
34.
Meek, J. 2000. Money and the meaning of life. The Guardian, 17 January. Available from http://www.guardian.co.uk/genes/article/0,2763,191862,00.html.
35.
Merton, R.K. 1973. The Sociology of science: Theoretical and empirical investigations. Chicago: University of Chicago Press.
NIH files counter-patent in breast cancer gene dispute. 1994. Nature372: 118.
38.
Nelkin, D., ed. 1992. Controversy—Politics of technical decisions, Newbury Park, CA: Sage.
39.
Nowak, R. 1994a. Breast cancer gene offers surprise. Science265: 1796-99.
40.
—. 1994b. NIH in danger of losing out on BRCA1 patent. Science266: 209.
41.
Oberbeck, S. 1996. Deny S.L. firm a patent, groups urge breast cancer studies will suffer, they say deny firm’s patent, groups urge. The Salt Lake Tribune, 22 May, B4.
42.
Orsenigo, L. 1989. The emergence of biotechnology: Institutions and markets in industrial innovation. London: Frances Pinter.
43.
Powell, W.W., and J. Owen-Smith. 1998. Universities and the market for intellectual property in the life sciences. Journal of Policy Analysis and Management17: 253-77.
44.
Rawling, A. 1994. The AIDS virus dispute—Awarding priority for the discovery of the human immunodeficiency virus. Science, Technology & Human Values19: 342-60.
45.
Rubin, S.C., I. Benjamin, K. Behbakht, H. Takahashi, M.A. Morgan, V.A. LiVolsi, A. Berchuck, M.G. Muto, J.E. Garber, B.L. Weber, H.T. Lynch, and J. Boyd. 1996. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. The New England Journal of Medicine335: 1413-16.
46.
Satagopan, J.M., K. Offit, W. Foulkes, M.E. Robson, S. Wacholder, C.M. Eng, S.E. Karp, and C.B. Begg. 2001. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiology, Biomarkers & Prevention, 10: 467-73.
47.
Schrag, D., K.M. Kuntz, J.E. Garber, and J.C. Weeks 1997. Decision analysis—Effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. The New England Journal of Medicine336: 1465-71.
48.
Senker, J., and R. Van Vliet, eds. 1998. Biotechnology and competitive advantage: Europe’s firms and the US challenge. Cheltenham, UK: Edward Elgar.
49.
Simon, B. 1999. Undead science: Making sense of cold fusion after the (arti)fact. Social Studies of Science29: 61-85.
50.
Skolnick, A.A. 1995. Cancer gene patent dispute settled. Journal of the American Medical Association273: 833.
51.
Struewing, J.P., P. Hartge, S. Wacholder, S.M. Baker, M. Berlin, M. McAdams, M.M. Timmerman, L.C. Brody, and M.A. Tucker. 1997. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. The New England Journal of Medicine336: 1401-8.
52.
Swann, G.M.P., M. Prevezer, and D. Stout, eds. 1998. The dynamics of industrial clustering: International comparisons in computing and biotechnology. New York: Oxford University Press.
53.
Temple, L.K.F., R.S. McLeod, S. Gallinger, and J.G. Wright. 2001. Defining disease in the genomics era. Science293: 807-8.
54.
Thackray, A., ed. 1998. Private science—Biotechnology and the rise of the molecular sciences. Philadelphia: University of Pennsylvania Press.
55.
Waldholz, M. 1994. Finding breast cancer gene is battle, not war, won. The Wall Street Journal, 15 September, B1, B5.
